A research team led by Deputy Director Jenn-Jong Young from the National Defense Medical Center has successfully developed a new type of cationic lipid nanocarrier. This nanocarrier can efficiently deliver drugs or vaccines into cells, especially cancer cells, with a high rate of cellular uptake. Produced using a single-step microfluidic method, this breakthrough is not only simple, eco-friendly, and rapid but also offers high reproducibility, significantly shortening the time to market.

Revolutionary Technology: Opening New Frontiers in Drug Delivery

Traditional drug delivery methods often face issues such as poor drug stability and low bioavailability, resulting in suboptimal therapeutic effects. The new nanocarrier developed by Young's team overcomes these challenges by coating lipid nanoparticles with cationic polysaccharides, giving the surface a positive charge. This allows the nanocarrier to effectively interact with the negatively charged cell membranes, significantly increasing cellular uptake. Experimental results show that the uptake efficiency of this nanocarrier in cancer cells is 3 to 8 times higher than in normal cells, with the added benefit of cytotoxicity to cancer cells. More importantly, this nanocarrier can efficiently deliver anticancer drugs to tumor sites and release the drugs within the tumor microenvironment, leading to improved therapeutic outcomes.

Multiple Advantages and Unlimited Potential Applications

Efficient Drug Delivery: As a targeted drug delivery system for anticancer drugs, it enhances therapeutic effects while reducing side effects, improving the quality of life for patients. Initial research has shown that encapsulating anticancer drugs in this nanocarrier can significantly inhibit tumor growth and extend survival in animal models.

Vaccine Adjuvant: The nanocarrier can effectively deliver nucleic acid and protein vaccines into cells, triggering a strong immune response, shortening the immunization period, and enhancing vaccine efficacy. Animal studies have shown that vaccines using this nanocarrier adjuvant induce higher concentrations of specific antibodies and offer longer-lasting protection.

Versatile Dosage Forms: The cationic polysaccharides exhibit mucosal adhesion properties, allowing for the development of various dosage forms, such as injectables, oral tablets, and nasal sprays, expanding its clinical applications. For example, for respiratory diseases, a nasal spray could be developed to deliver drugs directly to the affected area.

Streamlined Production Process Accelerates Time to Market

Traditional nanocarrier production methods are complex and challenging to scale up. The team’s use of a single-step microfluidic method simplifies the process while allowing precise control over nanoparticle size and surface properties. Crucially, this microfluidic technology enables the direct transfer of laboratory production parameters to factory-scale manufacturing, significantly shortening the time needed to bring products to market.

Deputy Director Young noted that this research opens new possibilities in the fields of drug delivery and vaccine development. In the future, the team aims to further optimize the design of the nanocarrier, exploring its potential applications not only in cancer and vaccines but also in the treatment of other diseases, such as genetic and neurodegenerative disorders. The team plans to collaborate with clinicians to apply this technology across a wide range of therapeutic areas.

Resource (mandarin): 新型奈米載體高效送藥 同步毒殺腫瘤細胞！